Disseminated Enteroviral Infection Associated with Obinutuzumab.
Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.
Claire
C
Dendle
Michael
M
Gilbertson
Tony M
TM
Korman
Vera
V
Golder
Eric
E
Morand
Stephen
S
Opat
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004769:Enterovirus Infections / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008590:Meningoencephalitis / Q000175:diagnosis* / Q000209:etiology; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C543332:obinutuzumab
CD 20 monoclonal antibody; dermatomyositis; enterovirus; obinutuzumab; rituximab; viruses